Autoimmune overlap syndromes

Hepatology

Volumn 33, Issue 4, 2001, Pages 994-1002

  Woodward, J ^a   Neuberger, J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; HUMAN; LIVER DISEASE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW;

EID: 0035080764     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.23316     Document Type: Article

References (112)

1. A unified concept of autoimmune hepatitis
2. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis
3. Clinical spectrum and heterogeneity of autoimmune hepatitis
4. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen
5. Autoantibodies against the human asialoglycoprotein receptor: Effects of therapy in autoimmune and virus-induced chronic active hepatitis
6. Autoimmune hepatitis in childhood: A 20 year experience
7. Meeting report
8. Frequency and nature of the variant syndromes of autoimmune liver disease
9. Primary biliary cirrhosis: The prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome
10. Sjogren's syndrome in patients with primary biliary cirrhosis
11. Definition and epidemiology of primary biliary cirrhosis
12. Natural history of early primary biliary cirrhosis
13. Autoimmune cholangitis: A variant of primary biliary cirrhosis
14. Antimitochondrial antibody-negative primary biliary cirrhosis
15. Antimitochondrial antibodies in primary biliary cirrhosis
16. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis
17. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis
18. Comparison of the clinicopathological features of primary sclerosing cholangitis and primary biliary cirrhosis
19. Primary sclerosing cholangitis: A review of its clinical features, cholangiography and hepatic histology
20. Granulomas in primary sclerosing cholangitis
21. Isolated granulomas in Hodgkins disease
22. Drug induced and toxic granulomatous hepatitis
23. Hepatic granulomas following liver transplantation. Clinicopathologic features in 42 patients
24. Granulomatous cholangitis in chronic hepatitis C: A new diagnostic problem in liver pathology
25. Primary sclerosing cholangitis as an autoimmune disease: Pros and cons
26. Primary sclerosing cholangitis: A review of its clinical features, cholangiography and hepatic histology
27. Histological classification of autoimmune cholestatic liver diseases
28. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure
29. Natural history of AIDS-related sclerosing cholangitis: A study of 20 cases
30. Sclerosing cholangitis and histiocytosis X
31. Antineutrophil cytoplasmic antibodies in chronic liver diseases: Prevalence, titre, specificity and 1gG subclass
32. High titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis
33. Primary sclerosing cholangitis
34. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis
35. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression
36. Behavior and significance of autoantibodies in type I autoimmune hepatitis
37. Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis
38. Validation of scoring system for diagnosis of autoimmune hepatitis
39. Pathology of vanishing bile duct syndromes
40. A cholangitis with antinuclear antibodies (immunocholangitis) resembling chronic non-suppurative destructive cholangitis
41. Primary autoimmune cholangitis: An alternative to antimitochondrial antibody-negative primary biliary cirrhosis
42. Antimitochondrial antibody negative primary biliary cirrhosis: A distinct syndrome of autoimmune cholangitis
43. Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis
44. Antimitochondrial antibody negative chronic non-suppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis?
45. Comparison of the clinical features and clinical course of antimitochondrial antibody positive and negative primary biliary cirrhosis
46. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies
47. Immunological study of anti-M2 in antimitochondrial antibody negative primary biliary cirrhosis
48. Autoimmune cholangitis and primary biliary cirrhosis - An autoimmune enigma
49. Detection of IgA, IgM and IgG subclassaed of anti-M2 antibody by imunoblotting in autoimmune cholangitis: Is autoimmune cholangitis an early stage of primary biliary cirrhosis?
50. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with anitmitochondrial antibody-negative primary biliary cirrhosis
51. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis
52. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis
53. Antibodies to carbonic anhydrase in patients with immune cholangiopathies
54. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis irrespective of antimitochondrial antibody status
55. The ability of carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients
56. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena?
57. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome
58. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis
59. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for its being a hepatitic form fo PBC in genetically susceptible individuals
60. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
61. Autoimmune choangiopathy: The result of consecutive primary biliary cirrhosis and autoimmune hepatitis?
62. Autoimmune chronic active hepatitis responsive to immunosuppressive therapy evolving into a typical primary biliary cirrhosis syndrome: A case report
63. Association of autoimmune active hepatitis with HLA-A1,B8
64. Primary biliary cirrhosis: Association with class II major histocompatibility complex antigens
65. A 28-year old woman with a combined hepatitic/cholestatic syndrome
66. Autoimmune chronic active hepatitis (lupoid hepatitis) and primary sclerosing cholangitis in two young adult females
67. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis
68. Autoimmune chronic active hepatitis evolving to primary sclerosing cholangitis: Evidence for a common pathogenesis
69. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis
70. Overlap between type I autoimmune hepatitis and primary sclerosing cholangitis
71. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases
72. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system
73. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis
74. Diagnosis of primary sclerosing cholangitis - Autoimmune hepatitis overlap syndrome: To score or not to score?
75. Primary sclerosing cholangitis in childhood
76. Primary sclerosing cholangitis in 32 children: Clinical, laboratory and radiographic features, with survival analysis
77. Evolution from autoimmune hepatitis to sclerosing cholangitis documented by serial cholangiographic studies
78. Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome
79. Immunization of experimental animals with dihydrolipoamide acetlytransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis
80. Primary biliary cirrhosis - An infectious disease?
81. HLA DRB4 0101-restricted immunodominant T-cell epitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: Evidence of molecular mimicry in human autoimmune disease
82. Class I and class II major histocompatibility complex antigen expression on hepatocytes: A study in children with liver disease
83. Association of primary sclerosing cholangitis with HLA-B8
84. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis-C infected liver
85. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis
86. Prognosis of histological cirrhosis in type I autoimmune hepatitis
87. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission
88. A pilot double-blind, controlled 1 year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss
89. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three year results
90. A prospective controlled trial of azathioprine in primary biliary cirrhosis
91. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial
92. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double blind, randomised controlled study
93. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
94. The Canadian multicenter double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
95. A randomized double blind, placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
96. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
97. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis and effect of ursodeoxycholic acid treatment
98. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration
99. Hepatic expression of class I and class II major histocompatibility molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid
100. Randomised controlled trials for ursodeoxycholic acid treatment of primary biliary cirrhosis: A meta-analysis
101. Combined analysis of randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
102. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo controlled trial
103. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo-controlled study period
104. Ursodiol for primary sclerosing cholangitis
105. Oral Budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial
106. Budesonide in the treatment of patients with primary biliary cirrhosis with suboptimal response to ursodeoxyxholic acid
107. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic hepatitis: A dose-response study
108. Ursodeoxycholic acid therapy in chronic active hepatitis
109. Ursodeoxycholic acid as adjunctive therapy for problematic type I autoimmune hepatitis: A randomized placebo-controlled treatment trial
110. Treatment of autoimmune cholangitis
111. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation
112. Primary biliary cirrhosis-autoimmune hepatitis overlap. Corticoresistance and effective treatment by cyclosporine A